Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INCR Stock Forecast 2026-2027
$0.84
Current Price
$45.87M
Market Cap
Buy 8
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to INCR Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
INCR Price Momentum
-5.6%
1 Week Change
+10.5%
1 Month Change
-47.2%
1 Year Change
-7.7%
Year-to-Date Change
-52.6%
From 52W High of $1.77
+23.4%
From 52W Low of $0.68
📊 TOP ANALYST CALLS
Did INCR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if InterCure is one of their latest high-conviction picks.
Latest INCR Stock Price Targets & Analyst Predictions
INCR has shown a year-to-date change of -7.7% and a 1-year change of -47.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for INCR. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INCR Analyst Ratings
8
Buy
4
Hold
0
Sell
INCR Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.84
Latest INCR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INCR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 12, 2023 | TD Cowen | Vivien Azer | Outperform | Maintains | $5.00 |
| Dec 11, 2017 | Barclays | Jack Meehan | Equal-Weight | Initiates | $40.00 |
| Nov 14, 2017 | Credit Suisse | Erin Wilson | Outperform | Maintains | $54.00 |
| Nov 13, 2017 | Keybanc | Donald Hooker | Overweight | Maintains | $46.00 |
| Nov 10, 2017 | Baird | Eric Coldwell | Outperform | Maintains | $46.00 |
| Aug 17, 2016 | Jefferies | Buy | Maintains | $55.00 | |
| Aug 12, 2016 | Goldman Sachs | Buy | Maintains | $62.00 | |
| Apr 18, 2016 | Avondale Partners | Market Perform | Maintains | $47.00 | |
| Sep 1, 2015 | Jefferies | Buy | Upgrade | $51.00 | |
| May 27, 2015 | Jefferies | Hold | Maintains | $37.00 | |
| Feb 12, 2015 | Baird | Outperform | Upgrade | $29.00 |
InterCure Ltd. (INCR) Competitors
The following stocks are similar to InterCure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
InterCure Ltd. (INCR) Financial Data
InterCure Ltd. has a market capitalization of $45.87M with a P/E ratio of 22.2x. The company generates $270.20M in trailing twelve-month revenue with a -13.2% profit margin.
Revenue growth is +23.9% quarter-over-quarter, while maintaining an operating margin of -9.0% and return on equity of -9.3%.
Valuation Metrics
Market Cap
$45.87M
Enterprise Value
$182.41M
P/E Ratio
22.2x
PEG Ratio
-0.6x
Price/Sales
0.2x
Growth & Margins
Revenue Growth (YoY)
+23.9%
Gross Margin
+31.9%
Operating Margin
-9.0%
Net Margin
-13.2%
EPS Growth
+7.5%
Financial Health
Cash/Price Ratio
N/A
Current Ratio
1.5x
Debt/Equity
45.1x
ROE
-9.3%
ROA
-2.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
InterCure Ltd. (INCR) Business Model
About InterCure Ltd.
What They Do
Develops and distributes cannabis-based pharmaceutical products.
Business Model
Intercure Ltd. generates revenue by producing and selling a diverse range of cannabis-based products aimed at both therapeutic and wellness markets. The company utilizes advanced cultivation techniques and proprietary research and development to ensure high-quality offerings. Strategic partnerships with global pharmaceutical and wellness leaders further enhance its market presence and innovation.
Additional Information
With operations in multiple countries, Intercure is positioned as a key player in the medical cannabis industry. It is committed to scientific research and regulatory compliance, which aids in the integration of medical cannabis into mainstream healthcare. The company's involvement in clinical studies and cannabinoid pharmacology emphasizes its pivotal role in improving health outcomes.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
320
CEO
Mr. Alexander Rabinovich
Country
Israel
IPO Year
2021
Website
www.intercure.coInterCure Ltd. (INCR) Latest News & Analysis
Latest News
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
8 days ago
Quick Summary
The Company reported NIS 270M in revenue, NIS 37M net loss, NIS 47M in adjusted EBITDA, and NIS 17M positive operating cash flow, marking 12 consecutive halves of positive adjusted EBITDA.
Why It Matters
The Company’s strong revenue and consistent positive Adjusted EBITDA indicate resilience and recovery, which may boost investor confidence and enhance stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
InterCure Ltd. (Nasdaq: INCR) received a notice from Nasdaq for non-compliance with Listing Rule 5450(a)(2) due to its share price being under $1.00 for 30 consecutive days.
Why It Matters
InterCure Ltd.'s non-compliance with Nasdaq's listing rule could lead to delisting, affecting share liquidity and investor confidence, potentially driving down stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
InterCure estimates NIS 265 million revenue for 2025 and reports positive Adjusted EBITDA for the twelfth consecutive half-year.
Why It Matters
InterCure's strong revenue forecast and consistent positive Adjusted EBITDA indicate financial stability and growth potential, attracting investor confidence and suggesting a healthy operational performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
InterCure and Cannasoul have formalized a research partnership, integrating InterCure's pharmaceutical platform with Cannasoul's analytics and scientific innovation.
Why It Matters
The partnership enhances InterCure's capabilities and market position in pharmaceuticals, potentially leading to innovative products and increased revenue, influencing investor sentiment positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
7 months ago
Quick Summary
The Company achieved NIS 130 million in revenue and NIS 12 million in positive operating cash flow, marking its eleventh half of positive Adjusted EBITDA amid Israel's recovery.
Why It Matters
Strong revenue and positive cash flow indicate financial health and operational efficiency, reflecting a resilient business model that may attract investor confidence and potential growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
7 months ago
Quick Summary
InterCure has acquired a leading cannabis company, enhancing its commercial expansion by gaining access to premium American brands and advanced cultivation technologies.
Why It Matters
InterCure's acquisition enhances its market position and product offering, potentially driving revenue growth and investor confidence in the expanding cannabis sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About INCR Stock
What is InterCure Ltd.'s (INCR) stock forecast for 2026?
Analyst forecasts for InterCure Ltd. (INCR) are not currently available. The stock is trading at $0.84.
Is INCR stock a good investment in 2026?
According to current analyst ratings, INCR has 8 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INCR stock?
Price predictions from Wall Street analysts for INCR are not currently available. The stock is trading at $0.84.
What is InterCure Ltd.'s business model?
Intercure Ltd. generates revenue by producing and selling a diverse range of cannabis-based products aimed at both therapeutic and wellness markets. The company utilizes advanced cultivation techniques and proprietary research and development to ensure high-quality offerings. Strategic partnerships with global pharmaceutical and wellness leaders further enhance its market presence and innovation.
What is the highest forecasted price for INCR InterCure Ltd.?
Price targets from Wall Street analysts for INCR are not currently available. The stock is trading at $0.84.
What is the lowest forecasted price for INCR InterCure Ltd.?
Price targets from Wall Street analysts for INCR are not currently available. The stock is trading at $0.84.
What is the overall INCR consensus from analysts for InterCure Ltd.?
The overall analyst consensus for INCR is bullish. Out of 6 Wall Street analysts, 8 rate it as Buy, 4 as Hold, and 0 as Sell.
How accurate are INCR stock price projections?
Stock price projections, including those for InterCure Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 8:45 AM UTC